Replimune Group, Inc. (NASDAQ:REPL) Shares Acquired by Vanguard Group Inc.

Vanguard Group Inc. grew its holdings in Replimune Group, Inc. (NASDAQ:REPL - Free Report) by 3.7% in the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 3,595,848 shares of the company's stock after buying an additional 129,601 shares during the period. Vanguard Group Inc. owned 5.26% of Replimune Group worth $43,546,000 at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. Geode Capital Management LLC increased its holdings in shares of Replimune Group by 17.9% in the third quarter. Geode Capital Management LLC now owns 1,428,301 shares of the company's stock valued at $15,657,000 after purchasing an additional 217,308 shares during the period. Barclays PLC lifted its stake in shares of Replimune Group by 165.5% in the 3rd quarter. Barclays PLC now owns 158,491 shares of the company's stock worth $1,738,000 after acquiring an additional 98,791 shares during the period. Victory Capital Management Inc. purchased a new stake in shares of Replimune Group in the fourth quarter valued at about $543,000. Swiss National Bank raised its holdings in Replimune Group by 57.4% during the fourth quarter. Swiss National Bank now owns 103,700 shares of the company's stock worth $1,256,000 after purchasing an additional 37,800 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Replimune Group by 102.1% in the third quarter. State Street Corp now owns 2,340,042 shares of the company's stock valued at $25,647,000 after buying an additional 1,182,181 shares in the last quarter. Institutional investors and hedge funds own 92.53% of the company's stock.

Wall Street Analysts Forecast Growth

REPL has been the topic of a number of research analyst reports. BMO Capital Markets boosted their target price on Replimune Group from $18.00 to $27.00 and gave the stock an "outperform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. raised their target price on shares of Replimune Group from $16.00 to $18.00 and gave the company an "overweight" rating in a report on Wednesday, February 26th. Finally, HC Wainwright increased their price target on shares of Replimune Group from $21.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, February 13th. Seven analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company's stock. According to MarketBeat.com, Replimune Group has an average rating of "Buy" and a consensus price target of $19.43.

Replimune Group Trading Up 0.5 %

REPL stock traded up $0.04 during trading on Thursday, reaching $7.67. 116,248 shares of the stock traded hands, compared to its average volume of 766,390. Replimune Group, Inc. has a 52-week low of $4.92 and a 52-week high of $17.00. The business's 50 day moving average price is $10.95 and its 200-day moving average price is $11.80. The company has a debt-to-equity ratio of 0.14, a current ratio of 11.43 and a quick ratio of 11.43. The firm has a market capitalization of $590.71 million, a PE ratio of -2.49 and a beta of 1.26.

Replimune Group (NASDAQ:REPL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The company reported ($0.79) earnings per share for the quarter, missing the consensus estimate of ($0.70) by ($0.09). As a group, sell-side analysts forecast that Replimune Group, Inc. will post -2.97 earnings per share for the current year.

Replimune Group Company Profile

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.